Literature DB >> 31579066

MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway.

Qing Wang1, Feng Geng1, Haomin Zhou1, Yecheng Chen1, Juan Du1, Xinyu Zhang1, Dandan Song1, Hongwen Zhao1.   

Abstract

Mineral dust-induced gene (MDIG) is a proto- oncogene associated with lung cancer that serves a key role in the biological processes of tumorigenesis. The aim of the present study was to determine whether MDIG is involved in cisplatin (DDP) resistance in lung adenocarcinoma, and to investigate the associated molecular mechanism. In the present study, MDIG-knockdown and MDIG-overexpressing A549 cells and DDP-resistant A549/DDP cells were initially constructed, and then the mRNA and protein expression levels of MDIG and ATP-binding cassette (ABC) transporters (ABCB1, ABCC1, ABCG2), and the expression levels of the major associated proteins in the WNT/β-catenin pathway were determined by reverse transcription-quantitative PCR and Western blotting experiments. The results revealed that the mRNA and protein expression levels of MDIG in A549/DDP cells were significantly higher compared with those in A549 cells, and that the protein expression levels of MDIG increased in a dose-dependent manner with increasing DDP concentrations. Overexpression of MDIG in A549 and A549/DDP cells led to an increase in the IC50 value, whereas silencing of MDIG led to a clear reduction in the IC50 value. The overexpression of MDIG in the A549 and A549/DDP cells markedly upregulated the mRNA and protein expression levels of ABCB1, ABCC1, ABCG2, WNT family member 5A, WNT family member 3A and active β-catenin, and these were markedly decreased following MDIG silencing. Taken together, these results demonstrated that the DDP resistance of lung adenocarcinoma may be associated with an upregulation of MDIG expression, and that the expression levels of MDIG are positively associated with the degree of DDP resistance. Furthermore, MDIG promoted the expression of ABC transporters in tumor cells by activating the WNT/β-catenin signaling pathway, which may, in turn, lead to DDP resistance in lung adenocarcinoma.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  ATP-binding cassette transporter; WNT/β-catenin pathway; lung cancer; mineral dust-induced gene; multidrug resistance

Year:  2019        PMID: 31579066      PMCID: PMC6757258          DOI: 10.3892/ol.2019.10774

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma.

Authors:  Suguru Fukahori; Hirohisa Yano; Makoto Tsuneoka; Yoshiaki Tanaka; Minoru Yagi; Michihiko Kuwano; Tatsuro Tajiri; Tomoaki Taguchi; Masazumi Tsuneyoshi; Masamichi Kojiro
Journal:  J Pediatr Surg       Date:  2007-11       Impact factor: 2.545

2.  Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.

Authors:  C Calatozzolo; M Gelati; E Ciusani; F L Sciacca; B Pollo; L Cajola; C Marras; A Silvani; L Vitellaro-Zuccarello; D Croci; A Boiardi; A Salmaggi
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

3.  The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer.

Authors:  Yadong Zhang; Yongju Lu; Bao-Zhu Yuan; Vince Castranova; Xianglin Shi; John L Stauffer; Laurence M Demers; Fei Chen
Journal:  Oncogene       Date:  2005-07-21       Impact factor: 9.867

4.  The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

Authors:  Zhi Shi; Smitaben Parmar; Xing-Xiang Peng; Tong Shen; Robert W Robey; Susan E Bates; Li-Wu Fu; Yining Shao; Yang-Min Chen; Feiyang Zang; Zhe-Sheng Chen
Journal:  Oncol Rep       Date:  2009-02       Impact factor: 3.906

5.  A novel myc target gene, mina53, that is involved in cell proliferation.

Authors:  Makoto Tsuneoka; Yoshiro Koda; Mikiko Soejima; Kwesi Teye; Hiroshi Kimura
Journal:  J Biol Chem       Date:  2002-06-28       Impact factor: 5.157

6.  Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma.

Authors:  Sachiko Ogasawara; Mina Komuta; Osamu Nakashima; Jun Akiba; Makoto Tsuneoka; Hirohisa Yano
Journal:  Hepatol Res       Date:  2010-01-11       Impact factor: 4.288

7.  Increased expression of a Myc target gene Mina53 in human colon cancer.

Authors:  Kwesi Teye; Makoto Tsuneoka; Nobuyuki Arima; Yoshiro Koda; Yasuhiro Nakamura; Yoichi Ueta; Kazuo Shirouzu; Hiroshi Kimura
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

8.  Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.

Authors:  Yuanyuan Guo; Min Chu; Songwei Tan; Shuang Zhao; Hanxiao Liu; Ben Oketch Otieno; Xiangliang Yang; Chuanrui Xu; Zhiping Zhang
Journal:  Mol Pharm       Date:  2013-11-21       Impact factor: 4.939

9.  Oncoprotein mdig contributes to silica-induced pulmonary fibrosis by altering balance between Th17 and Treg T cells.

Authors:  Chitra Thakur; Michael Wolfarth; Jiaying Sun; Yadong Zhang; Yongju Lu; Lori Battelli; Dale W Porter; Fei Chen
Journal:  Oncotarget       Date:  2015-02-28

10.  Paradoxical roles of mineral dust induced gene on cell proliferation and migration/invasion.

Authors:  Miaomiao Yu; Jiaying Sun; Chitra Thakur; Bailing Chen; Yongju Lu; Hongwen Zhao; Fei Chen
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

View more
  9 in total

1.  MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer.

Authors:  Feng Geng; Wei Yang; Dandan Song; Haijia Hou; Bing Han; Yecheng Chen; Hongwen Zhao
Journal:  Int J Oncol       Date:  2022-05-18       Impact factor: 5.884

2.  ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.

Authors:  Changfu Liu; Wenge Xing; Haipeng Yu; Weihao Zhang; Tongguo Si
Journal:  Cancer Cell Int       Date:  2021-02-16       Impact factor: 5.722

3.  Integrative analysis of exosomal microRNA-149-5p in lung adenocarcinoma.

Authors:  Wen Tian; He Yang; Baosen Zhou
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

4.  Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance.

Authors:  A K M Nawshad Hossian; Fatema Tuz Zahra; Sagun Poudel; Camille F Abshire; Paula Polk; Jone Garai; Jovanny Zabaleta; Constantinos M Mikelis; George Mattheolabakis
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

5.  Increase in Anticancer Drug-Induced Toxicity by Fisetin in Lung Adenocarcinoma A549 Spheroid Cells Mediated by the Reduction of Claudin-2 Expression.

Authors:  Hiroaki Eguchi; Riho Kimura; Haruka Matsunaga; Toshiyuki Matsunaga; Yuta Yoshino; Satoshi Endo; Akira Ikari
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

6.  SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.

Authors:  Wei Yang; Bing Han; Yecheng Chen; Feng Geng
Journal:  Aging (Albany NY)       Date:  2022-08-13       Impact factor: 5.955

7.  KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.

Authors:  Luca Jaromi; Veronika Csongei; Monika Vesel; ElHusseiny Mohamed Mahmud Abdelwahab; Amina Soltani; Zsofia Torok; Gabor Smuk; Veronika Sarosi; Judit Erzsebet Pongracz
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

8.  Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor.

Authors:  Xiaoqing Wang; Guoqiang Du; Yidi Wu; Yongfei Zhang; Feng Guo; Wei Liu; Rongde Wu
Journal:  Int J Oncol       Date:  2019-12-20       Impact factor: 5.650

9.  Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.

Authors:  Dan Chu; Pengpeng Li; Yameng Li; Jiang Shi; Siyuan Huang; Pengfei Jiao
Journal:  Thorac Cancer       Date:  2021-09-14       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.